PURPOSE: Morbidity from acute graft-versus-host disease (GVHD) limits the success of allogeneic hematopoietic stem-cell transplantation (HSCT) to treat malignancy. Interleukin-7 (IL-7), the principal homeostatic cytokine for T cells, is required for acute GVHD in murine models. In contrast to inflammatory cytokines (eg, IL-2, tumor necrosis factor alpha), IL-7 has not been studied extensively in the clinical transplant setting relative to its relationship with acute GVHD. PATIENTS AND METHODS: We evaluated the association of serum IL-7 levels with acute GVHD in 31 patients who were uniformly treated in a prospective clinical trial with reduced-intensity allogeneic HSCT from human leukocyte antigen-identical siblings. GVHD prophylaxis consisted of cyclosporine and methotrexate. Serum IL-7 levels and lymphocyte populations were determined at enrollment, the day of transplantation before the allograft infusion, and at specified intervals through 12 months post-transplantation. RESULTS: As expected, IL-7 levels were inversely correlated with T-cell populations (P < .00001). Acute GVHD was significantly associated with higher IL-7 levels at day +7 (P = .01) and day +14 (P = .00003) post-transplantation as well as with the allograft CD34(+) cell dose (P = .01). IL-7 levels at day +14 also correlated with the severity of acute GVHD (P < .0001). In logistic regression models, these factors were highly sensitive (up to 86%) and specific (100%) for classifying whether patients developed acute GVHD. CONCLUSION: These data support preclinical observations that IL-7 plays a critical role in inducing acute GVHD and provide a rational basis for novel approaches to prevent and treat acute GVHD through modulation of the IL-7 pathway.
PURPOSE: Morbidity from acute graft-versus-host disease (GVHD) limits the success of allogeneic hematopoietic stem-cell transplantation (HSCT) to treat malignancy. Interleukin-7 (IL-7), the principal homeostatic cytokine for T cells, is required for acute GVHD in murine models. In contrast to inflammatory cytokines (eg, IL-2, tumor necrosis factor alpha), IL-7 has not been studied extensively in the clinical transplant setting relative to its relationship with acute GVHD. PATIENTS AND METHODS: We evaluated the association of serum IL-7 levels with acute GVHD in 31 patients who were uniformly treated in a prospective clinical trial with reduced-intensity allogeneic HSCT from human leukocyte antigen-identical siblings. GVHD prophylaxis consisted of cyclosporine and methotrexate. Serum IL-7 levels and lymphocyte populations were determined at enrollment, the day of transplantation before the allograft infusion, and at specified intervals through 12 months post-transplantation. RESULTS: As expected, IL-7 levels were inversely correlated with T-cell populations (P < .00001). Acute GVHD was significantly associated with higher IL-7 levels at day +7 (P = .01) and day +14 (P = .00003) post-transplantation as well as with the allograft CD34(+) cell dose (P = .01). IL-7 levels at day +14 also correlated with the severity of acute GVHD (P < .0001). In logistic regression models, these factors were highly sensitive (up to 86%) and specific (100%) for classifying whether patients developed acute GVHD. CONCLUSION: These data support preclinical observations that IL-7 plays a critical role in inducing acute GVHD and provide a rational basis for novel approaches to prevent and treat acute GVHD through modulation of the IL-7 pathway.
Authors: E Holler; H J Kolb; A Möller; J Kempeni; S Liesenfeld; H Pechumer; W Lehmacher; G Ruckdeschel; B Gleixner; C Riedner Journal: Blood Date: 1990-02-15 Impact factor: 22.113
Authors: P A Rowlings; D Przepiorka; J P Klein; R P Gale; J R Passweg; P J Henslee-Downey; J Y Cahn; S Calderwood; A Gratwohl; G Socié; M M Abecasis; K A Sobocinski; M J Zhang; M M Horowitz Journal: Br J Haematol Date: 1997-06 Impact factor: 6.998
Authors: D Przepiorka; T L Smith; J Folloder; I Khouri; N T Ueno; R Mehra; M Körbling; Y O Huh; S Giralt; J Gajewski; M Donato; K Cleary; D Claxton; I Braunschweig; K van Besien; B S Andersson; P Anderlini; R Champlin Journal: Blood Date: 1999-08-15 Impact factor: 22.113
Authors: R Hofmeister; A R Khaled; N Benbernou; E Rajnavolgyi; K Muegge; S K Durum Journal: Cytokine Growth Factor Rev Date: 1999-03 Impact factor: 7.638
Authors: G B Vogelsang; A D Hess; A W Berkman; P J Tutschka; E R Farmer; P J Converse; G W Santos Journal: N Engl J Med Date: 1985-09-12 Impact factor: 91.245
Authors: D Przepiorka; D Weisdorf; P Martin; H G Klingemann; P Beatty; J Hows; E D Thomas Journal: Bone Marrow Transplant Date: 1995-06 Impact factor: 5.483
Authors: Jan Joseph Melenhorst; Xin Tian; Dihua Xu; Netanya G Sandler; Philip Scheinberg; Angelique Biancotto; Priscila Scheinberg; John Phil McCoy; Nancy F Hensel; Zach McIver; Daniel C Douek; Austin John Barrett Journal: Haematologica Date: 2011-12-01 Impact factor: 9.941
Authors: Evelyn Ullrich; Benjamin Abendroth; Johanna Rothamer; Carina Huber; Maike Büttner-Herold; Vera Buchele; Tina Vogler; Thomas Longerich; Sebastian Zundler; Simon Völkl; Andreas Beilhack; Stefan Rose-John; Stefan Wirtz; Georg F Weber; Sakhila Ghimire; Marina Kreutz; Ernst Holler; Andreas Mackensen; Markus F Neurath; Kai Hildner Journal: J Clin Invest Date: 2018-01-29 Impact factor: 14.808
Authors: R Zeiser; A Burchert; C Lengerke; M Verbeek; K Maas-Bauer; S K Metzelder; S Spoerl; M Ditschkowski; M Ecsedi; K Sockel; F Ayuk; S Ajib; F S de Fontbrune; I-K Na; L Penter; U Holtick; D Wolf; E Schuler; E Meyer; P Apostolova; H Bertz; R Marks; M Lübbert; R Wäsch; C Scheid; F Stölzel; R Ordemann; G Bug; G Kobbe; R Negrin; M Brune; A Spyridonidis; A Schmitt-Gräff; W van der Velden; G Huls; S Mielke; G U Grigoleit; J Kuball; R Flynn; G Ihorst; J Du; B R Blazar; R Arnold; N Kröger; J Passweg; J Halter; G Socié; D Beelen; C Peschel; A Neubauer; J Finke; J Duyster; N von Bubnoff Journal: Leukemia Date: 2015-07-31 Impact factor: 11.528